Marques Pedro, Gunawardana Kavinga, Grossman Ashley
Endocrinology Department , Instituto Português de Oncologia de Lisboa , Francisco Gentil, Rua Professor Lima Basto1099-023, Lisboa , Portugal ; Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford , Oxford , UK.
Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford , Oxford , UK.
Endocrinol Diabetes Metab Case Rep. 2015;2015:150078. doi: 10.1530/EDM-15-0078. Epub 2015 Sep 23.
Gestational diabetes insipidus (DI) is a rare complication of pregnancy, usually developing in the third trimester and remitting spontaneously 4-6 weeks post-partum. It is mainly caused by excessive vasopressinase activity, an enzyme expressed by placental trophoblasts which metabolises arginine vasopressin (AVP). Its diagnosis is challenging, and the treatment requires desmopressin. A 38-year-old Chinese woman was referred in the 37th week of her first single-gestation due to polyuria, nocturia and polydipsia. She was known to have gestational diabetes mellitus diagnosed in the second trimester, well-controlled with diet. Her medical history was unremarkable. Physical examination demonstrated decreased skin turgor; her blood pressure was 102/63 mmHg, heart rate 78 beats/min and weight 53 kg (BMI 22.6 kg/m(2)). Laboratory data revealed low urine osmolality 89 mOsmol/kg (350-1000), serum osmolality 293 mOsmol/kg (278-295), serum sodium 144 mmol/l (135-145), potassium 4.1 mmol/l (3.5-5.0), urea 2.2 mmol/l (2.5-6.7), glucose 3.5 mmol/l and HbA1c 5.3%. Bilirubin, alanine transaminase, alkaline phosphatase and full blood count were normal. The patient was started on desmopressin with improvement in her symptoms, and normalisation of serum and urine osmolality (280 and 310 mOsmol/kg respectively). A fetus was delivered at the 39th week without major problems. After delivery, desmopressin was stopped and she had no further evidence of polyuria, polydipsia or nocturia. Her sodium, serum/urine osmolality at 12-weeks post-partum were normal. A pituitary magnetic resonance imaging (MRI) revealed the neurohypophyseal T1-bright spot situated ectopically, with a normal adenohypophysis and infundibulum. She remains clinically well, currently breastfeeding, and off all medication. This case illustrates some challenges in the diagnosis and management of transient gestational DI.
Gestational DI is a rare complication of pregnancy occurring in two to four out of 100 000 pregnancies. It usually develops at the end of the second or third trimester of pregnancy and remits spontaneously 4-6 weeks after delivery.Gestational DI occurrence is related to excessive vasopressinase activity, an enzyme expressed by placental trophoblasts during pregnancy, which metabolises AVP. Its activity is proportional to the placental weight, explaining the higher vasopressinase activity in third trimester or in multiple pregnancies.Vasopressinase is metabolised by the liver, which most likely explains its higher concentrations in pregnant women with hepatic dysfunction, such acute fatty liver of pregnancy, HELLP syndrome, hepatitis and cirrhosis. Therefore, it is important to assess liver function in patients with gestational DI, and to be aware of the risk of DI in pregnant women with liver disease.Serum and urine osmolality are essential for the diagnosis, but other tests such as serum sodium, glucose, urea, creatinine, liver function may be informative. The water deprivation test is normally not recommended during pregnancy because it may lead to significant dehydration, but a pituitary MRI should be performed at some point to exclude lesions in the hypothalamo-pituitary region.These patients should be monitored for vital signs, fluid balance, body weight, fetal status, renal and liver function, and treated with desmopressin. The recommended doses are similar or slightly higher than those recommended for central DI in non-pregnant women, and should be titrated individually.
妊娠性尿崩症(DI)是妊娠罕见的并发症,通常在妊娠晚期出现,产后4 - 6周自行缓解。其主要由血管加压素酶活性过高引起,血管加压素酶是胎盘滋养层细胞表达的一种可代谢精氨酸血管加压素(AVP)的酶。其诊断具有挑战性,治疗需要去氨加压素。一名38岁的中国女性在首次单胎妊娠第37周时因多尿、夜尿和烦渴前来就诊。已知她在妊娠中期被诊断为妊娠期糖尿病,通过饮食控制良好。她的病史无异常。体格检查显示皮肤弹性降低;血压为102/63 mmHg,心率78次/分钟,体重53 kg(BMI 22.6 kg/m²)。实验室检查数据显示尿渗透压低至89 mOsmol/kg(350 - 1000),血清渗透压293 mOsmol/kg(278 - 295),血清钠144 mmol/L(135 - 145),钾4.1 mmol/L(3.5 - 5.0),尿素2.2 mmol/L(2.5 - 6.7),葡萄糖3.5 mmol/L,糖化血红蛋白5.3%。胆红素、丙氨酸转氨酶、碱性磷酸酶和全血细胞计数均正常。患者开始使用去氨加压素治疗,症状改善,血清和尿渗透压恢复正常(分别为280和310 mOsmol/kg)。在第39周分娩一胎儿,无重大问题。产后停用去氨加压素,她不再有多尿、烦渴或夜尿的症状。产后12周时她的钠、血清/尿渗透压均正常。垂体磁共振成像(MRI)显示神经垂体T1高信号异位,腺垂体和漏斗部正常。她目前临床状况良好,正在母乳喂养,未服用任何药物。该病例说明了短暂性妊娠性尿崩症诊断和管理中的一些挑战。
妊娠性尿崩症是妊娠罕见的并发症,每10万次妊娠中有2 - 4例发生。通常在妊娠第二或晚期出现,产后4 - 6周自行缓解。妊娠性尿崩症的发生与血管加压素酶活性过高有关,血管加压素酶是孕期胎盘滋养层细胞表达的一种可代谢AVP的酶。其活性与胎盘重量成正比,这解释了在妊娠晚期或多胎妊娠中血管加压素酶活性较高的原因。血管加压素酶由肝脏代谢,这很可能解释了其在患有肝功能障碍的孕妇(如妊娠急性脂肪肝、HELLP综合征、肝炎和肝硬化)中浓度较高的原因。因此,评估妊娠性尿崩症患者的肝功能很重要,并且要意识到患有肝病的孕妇发生尿崩症的风险。血清和尿渗透压对诊断至关重要,但其他检查如血清钠、葡萄糖、尿素、肌酐、肝功能检查也可能提供有用信息。通常不建议在孕期进行禁水试验,因为这可能导致严重脱水,但应在某个时间点进行垂体MRI检查以排除下丘脑 - 垂体区域的病变。这些患者应监测生命体征、液体平衡、体重、胎儿状况、肾功能和肝功能,并使用去氨加压素治疗。推荐剂量与非妊娠女性中枢性尿崩症的推荐剂量相似或略高,应个体化滴定。